Please assess the completion status of the following clinical trial:

Trial Title: Repetitive Transcranial Magnetic Stimulation as Treatment for Acute Suicidality in Adult Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18-60 years, of all races and ethnicities;~* Admitted voluntarily to the adult psychiatric inpatient at PRI;~* Suffering from a current depressive episode~* Reason for hospitalization should be a recent suicide attempt or suicidal ideation~* Current severe suicidal ideation defined by a score \>7 on the Beck Scale for Suicidal Ideation~* Ability to read, write and speak English.~Exclusion Criteria:~* History of dementia, neurovascular or neurodegenerative conditions~* Physical disabilities that prohibit task performance (such as blindness or deafness)~* Choosing to opt out of the research study.~* Additional exclusion criteria for TMS include the following:~  * a personal history or 1st degree relative with history of epilepsy;~ * a personal history of head injury, aneurysm, stroke, previous cranial neurosurgery, neurological, or migraines;~ * recent use of cocaine or alcohol;~ * ferromagnetic metal implants in the head or neck, active or inactive implants(including device leads), deep brain stimulators, cochlear implants or vagus nerve stimulators;~ * a pacemaker;~ * pregnancy (or the possibility of pregnancy);~ * Medications that lower seizure threshold (bupropion or tricyclic antidepressants, such as thorazine, clozapine, amitriptyline, amoxapine, Norpramin, Sinequan, Tofranil, Pamelor, Vivactil, or Surmontil). Other antidepressant and antipsychotic medications have been deemed exhibit a relatively low seizurogenic potential (Pisani et al. 2002).~ * Patients taking a medication for weight loss and depression called bupropion (Wellbutrin) they will be excluded because it may increase the likelihood of experiencing a seizure.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Active rTMS (Type: ACTIVE_COMPARATOR): Repetitive Transcranial Magnetic Stimulation (rTMS) will be delivered to the left PFC, deﬁned as a location 6 cm (cm) anterior to the right hand motor thumb area. A research nurse will deliver the treatments. rTMS will be delivered with a ﬁgure-eight coil at 120% motor threshold, 10 Hertz (Hz), 5 s (s) train duration, 20 s intertrain interval for 50 min (6000 pulses) 3 times daily for 3 days (total 9 sessions, 54,000 stimuli).
- Sham rTMS (Type: SHAM_COMPARATOR): Parameters for sham Repetitive Transcranial Magnetic Stimulation (rTMS) are identical to those for active stimulation except that aluminum plate blocks the propagation of a magnetic field. The sound and physical sensation is the same as with the active coil while been biologically inactive.

Based on this trial design, predict the completion outcome and termination type (if applicable).